<DOC>
	<DOCNO>NCT00777101</DOCNO>
	<brief_summary>This study experimental drug ( neratinib ) versus combination drug ( lapatinib capecitabine ) woman erbB-2 ( HER-2 ) positive metastatic locally advanced breast cancer . The goal study compare two regimen shrink tumor extend life woman erbB2 ( HER2 ) positive breast cancer . The study also compare safety two regimen compare quality life patient take two regimen .</brief_summary>
	<brief_title>Study Evaluating Neratinib Versus Lapatinib Plus Capecitabine For ErbB2 Positive Advanced Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Lapatinib</mesh_term>
	<criteria>Stage IIIB , IIIC , IV erbB2 ( HER2 ) positive breast cancer Prior use Herceptin ( trastuzumab ) , taxane Adequate cardiac renal function More 2 prior Herceptin ( trastuzumab ) regimens prior use Xeloda ( capecitabine ) / Tykerb ( lapatinib ) [ Tyverb ] Bone site disease Active central nervous system metastasis ( subject stable anticonvulsant steroid ) Significant gastrointestinal disorder diarrhea major symptom</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>HER2</keyword>
	<keyword>ErbB2</keyword>
	<keyword>metastatic</keyword>
	<keyword>neratinib</keyword>
	<keyword>lapatinib</keyword>
	<keyword>capecitabine</keyword>
	<keyword>HKI-272</keyword>
	<keyword>Tykerb</keyword>
	<keyword>Tyverb</keyword>
	<keyword>Xeloda</keyword>
</DOC>